Search

Your search keyword '"Creutzberg, Carien L"' showing total 713 results
Start Over Author "Creutzberg, Carien L"
713 results on '"Creutzberg, Carien L"'

51. Data from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

Author

Workel, Hagma H., primary, Lubbers, Joyce M., primary, Arnold, Roland, primary, Prins, Thalina M., primary, van der Vlies, Pieter, primary, de Lange, Kim, primary, Bosse, Tjalling, primary, van Gool, Inge C., primary, Eggink, Florine A., primary, Wouters, Maartje C.A., primary, Komdeur, Fenne L., primary, van der Slikke, Elisabeth C., primary, Creutzberg, Carien L., primary, Kol, Arjan, primary, Plat, Annechien, primary, Glaire, Mark, primary, Church, David N., primary, Nijman, Hans W., primary, and de Bruyn, Marco, primary

Published
2023
Full Text
View/download PDF

52. Supplementary Table 7 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

Author

Workel, Hagma H., primary, Lubbers, Joyce M., primary, Arnold, Roland, primary, Prins, Thalina M., primary, van der Vlies, Pieter, primary, de Lange, Kim, primary, Bosse, Tjalling, primary, van Gool, Inge C., primary, Eggink, Florine A., primary, Wouters, Maartje C.A., primary, Komdeur, Fenne L., primary, van der Slikke, Elisabeth C., primary, Creutzberg, Carien L., primary, Kol, Arjan, primary, Plat, Annechien, primary, Glaire, Mark, primary, Church, David N., primary, Nijman, Hans W., primary, and de Bruyn, Marco, primary

Published
2023
Full Text
View/download PDF

53. Supplementary Tables 1-6, 8 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

Author

Workel, Hagma H., primary, Lubbers, Joyce M., primary, Arnold, Roland, primary, Prins, Thalina M., primary, van der Vlies, Pieter, primary, de Lange, Kim, primary, Bosse, Tjalling, primary, van Gool, Inge C., primary, Eggink, Florine A., primary, Wouters, Maartje C.A., primary, Komdeur, Fenne L., primary, van der Slikke, Elisabeth C., primary, Creutzberg, Carien L., primary, Kol, Arjan, primary, Plat, Annechien, primary, Glaire, Mark, primary, Church, David N., primary, Nijman, Hans W., primary, and de Bruyn, Marco, primary

Published
2023
Full Text
View/download PDF

54. Supplementary Figures from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

Author

Workel, Hagma H., primary, Lubbers, Joyce M., primary, Arnold, Roland, primary, Prins, Thalina M., primary, van der Vlies, Pieter, primary, de Lange, Kim, primary, Bosse, Tjalling, primary, van Gool, Inge C., primary, Eggink, Florine A., primary, Wouters, Maartje C.A., primary, Komdeur, Fenne L., primary, van der Slikke, Elisabeth C., primary, Creutzberg, Carien L., primary, Kol, Arjan, primary, Plat, Annechien, primary, Glaire, Mark, primary, Church, David N., primary, Nijman, Hans W., primary, and de Bruyn, Marco, primary

Published
2023
Full Text
View/download PDF

55. Supplementary Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer

Author

Horeweg, Nanda, primary, de Bruyn, Marco, primary, Nout, Remi A., primary, Stelloo, Ellen, primary, Kedzierska, Katarzyna, primary, León-Castillo, Alicia, primary, Plat, Annechien, primary, Mertz, Kirsten D., primary, Osse, Michelle, primary, Jürgenliemk-Schulz, Ina M., primary, Lutgens, Ludy C.H.W., primary, Jobsen, Jan J., primary, van der Steen-Banasik, Elzbieta M., primary, Smit, Vincent T., primary, Creutzberg, Carien L., primary, Bosse, Tjalling, primary, Nijman, Hans W., primary, Koelzer, Viktor H., primary, and Church, David N., primary

Published
2023
Full Text
View/download PDF

56. Supplementary figure 6 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Author

van Gool, Inge C., primary, Eggink, Florine A., primary, Freeman-Mills, Luke, primary, Stelloo, Ellen, primary, Marchi, Emanuele, primary, de Bruyn, Marco, primary, Palles, Claire, primary, Nout, Remi A., primary, de Kroon, Cor D., primary, Osse, Elisabeth M., primary, Klenerman, Paul, primary, Creutzberg, Carien L., primary, Tomlinson, Ian P.M., primary, Smit, Vincent T.H.B.M., primary, Nijman, Hans W., primary, Bosse, Tjalling, primary, and Church, David N., primary

Published
2023
Full Text
View/download PDF

57. Table S3 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

Author

Van Gool, Inge C., primary, Rayner, Emily, primary, Osse, Elisabeth M., primary, Nout, Remi A., primary, Creutzberg, Carien L., primary, Tomlinson, Ian P.M., primary, Church, David N., primary, Smit, Vincent T.H.B.M., primary, de Wind, Niels, primary, Bosse, Tjalling, primary, and Drost, Mark, primary

Published
2023
Full Text
View/download PDF

58. Supplementary figure 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Author

van Gool, Inge C., primary, Eggink, Florine A., primary, Freeman-Mills, Luke, primary, Stelloo, Ellen, primary, Marchi, Emanuele, primary, de Bruyn, Marco, primary, Palles, Claire, primary, Nout, Remi A., primary, de Kroon, Cor D., primary, Osse, Elisabeth M., primary, Klenerman, Paul, primary, Creutzberg, Carien L., primary, Tomlinson, Ian P.M., primary, Smit, Vincent T.H.B.M., primary, Nijman, Hans W., primary, Bosse, Tjalling, primary, and Church, David N., primary

Published
2023
Full Text
View/download PDF

59. Supplementary Table S5 from Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

Author

Stelloo, Ellen, primary, Nout, Remi A., primary, Osse, Elisabeth M., primary, Jürgenliemk-Schulz, Ina J., primary, Jobsen, Jan J., primary, Lutgens, Ludy C., primary, van der Steen-Banasik, Elzbieta M., primary, Nijman, Hans W., primary, Putter, Hein, primary, Bosse, Tjalling, primary, Creutzberg, Carien L., primary, and Smit, Vincent T.H.B.M., primary

Published
2023
Full Text
View/download PDF

60. Figure S1 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

Author

Van Gool, Inge C., primary, Rayner, Emily, primary, Osse, Elisabeth M., primary, Nout, Remi A., primary, Creutzberg, Carien L., primary, Tomlinson, Ian P.M., primary, Church, David N., primary, Smit, Vincent T.H.B.M., primary, de Wind, Niels, primary, Bosse, Tjalling, primary, and Drost, Mark, primary

Published
2023
Full Text
View/download PDF

61. Supplementary figure 4 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Author

van Gool, Inge C., primary, Eggink, Florine A., primary, Freeman-Mills, Luke, primary, Stelloo, Ellen, primary, Marchi, Emanuele, primary, de Bruyn, Marco, primary, Palles, Claire, primary, Nout, Remi A., primary, de Kroon, Cor D., primary, Osse, Elisabeth M., primary, Klenerman, Paul, primary, Creutzberg, Carien L., primary, Tomlinson, Ian P.M., primary, Smit, Vincent T.H.B.M., primary, Nijman, Hans W., primary, Bosse, Tjalling, primary, and Church, David N., primary

Published
2023
Full Text
View/download PDF

62. Supplementary table 2 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Author

van Gool, Inge C., primary, Eggink, Florine A., primary, Freeman-Mills, Luke, primary, Stelloo, Ellen, primary, Marchi, Emanuele, primary, de Bruyn, Marco, primary, Palles, Claire, primary, Nout, Remi A., primary, de Kroon, Cor D., primary, Osse, Elisabeth M., primary, Klenerman, Paul, primary, Creutzberg, Carien L., primary, Tomlinson, Ian P.M., primary, Smit, Vincent T.H.B.M., primary, Nijman, Hans W., primary, Bosse, Tjalling, primary, and Church, David N., primary

Published
2023
Full Text
View/download PDF

63. Figure S4 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma

Author

Depreeuw, Jeroen, primary, Stelloo, Ellen, primary, Osse, Elisabeth M., primary, Creutzberg, Carien L., primary, Nout, Remi A., primary, Moisse, Matthieu, primary, Garcia-Dios, Diego A., primary, Dewaele, Michael, primary, Willekens, Karen, primary, Marine, Jean-Christophe, primary, Matias-Guiu, Xavier, primary, Amant, Frédéric, primary, Lambrechts, Diether, primary, and Bosse, Tjalling, primary

Published
2023
Full Text
View/download PDF

64. Supplementary figure 5 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Author

van Gool, Inge C., primary, Eggink, Florine A., primary, Freeman-Mills, Luke, primary, Stelloo, Ellen, primary, Marchi, Emanuele, primary, de Bruyn, Marco, primary, Palles, Claire, primary, Nout, Remi A., primary, de Kroon, Cor D., primary, Osse, Elisabeth M., primary, Klenerman, Paul, primary, Creutzberg, Carien L., primary, Tomlinson, Ian P.M., primary, Smit, Vincent T.H.B.M., primary, Nijman, Hans W., primary, Bosse, Tjalling, primary, and Church, David N., primary

Published
2023
Full Text
View/download PDF

65. Supplementary Methods from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues

Author

Van Gool, Inge C., primary, Rayner, Emily, primary, Osse, Elisabeth M., primary, Nout, Remi A., primary, Creutzberg, Carien L., primary, Tomlinson, Ian P.M., primary, Church, David N., primary, Smit, Vincent T.H.B.M., primary, de Wind, Niels, primary, Bosse, Tjalling, primary, and Drost, Mark, primary

Published
2023
Full Text
View/download PDF

66. Supplementary figure 2 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Author

van Gool, Inge C., primary, Eggink, Florine A., primary, Freeman-Mills, Luke, primary, Stelloo, Ellen, primary, Marchi, Emanuele, primary, de Bruyn, Marco, primary, Palles, Claire, primary, Nout, Remi A., primary, de Kroon, Cor D., primary, Osse, Elisabeth M., primary, Klenerman, Paul, primary, Creutzberg, Carien L., primary, Tomlinson, Ian P.M., primary, Smit, Vincent T.H.B.M., primary, Nijman, Hans W., primary, Bosse, Tjalling, primary, and Church, David N., primary

Published
2023
Full Text
View/download PDF

67. Supplementary figure 3 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Author

van Gool, Inge C., primary, Eggink, Florine A., primary, Freeman-Mills, Luke, primary, Stelloo, Ellen, primary, Marchi, Emanuele, primary, de Bruyn, Marco, primary, Palles, Claire, primary, Nout, Remi A., primary, de Kroon, Cor D., primary, Osse, Elisabeth M., primary, Klenerman, Paul, primary, Creutzberg, Carien L., primary, Tomlinson, Ian P.M., primary, Smit, Vincent T.H.B.M., primary, Nijman, Hans W., primary, Bosse, Tjalling, primary, and Church, David N., primary

Published
2023
Full Text
View/download PDF

68. Supplementary table 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Author

van Gool, Inge C., primary, Eggink, Florine A., primary, Freeman-Mills, Luke, primary, Stelloo, Ellen, primary, Marchi, Emanuele, primary, de Bruyn, Marco, primary, Palles, Claire, primary, Nout, Remi A., primary, de Kroon, Cor D., primary, Osse, Elisabeth M., primary, Klenerman, Paul, primary, Creutzberg, Carien L., primary, Tomlinson, Ian P.M., primary, Smit, Vincent T.H.B.M., primary, Nijman, Hans W., primary, Bosse, Tjalling, primary, and Church, David N., primary

Published
2023
Full Text
View/download PDF

69. International validation of two EORTC questionnaires for assessment of health‐related quality of life for patients with high‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐HG29) and low‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐LG20)

Author

Oerlemans, S., Efficace, Fabio, Kyriakou, Charalampia, Freitas, Ana carolina, Shamieh, Omar, Creutzberg, Carien l., Lehmann, Jens, Petranovic, Duska, Nagele, Eva, Bredart, Anne, Dong, Dong, Scholz, Christian w., Caocci, Giovanni, Molica, Stefano, Griskevicius, Laimonas, Xochelli, Aliki, Kieffer, Jacobien m., Agelink van rentergem, Joost a., Alrjoub, Waleed, Mueller, Anja, Gomes da silva, Maria, Alves da costa, Filipa, Malak, Sandra, Cocks, Kim, Van de Poll‐Franse, L.V., Oerlemans, S., Efficace, Fabio, Kyriakou, Charalampia, Freitas, Ana carolina, Shamieh, Omar, Creutzberg, Carien l., Lehmann, Jens, Petranovic, Duska, Nagele, Eva, Bredart, Anne, Dong, Dong, Scholz, Christian w., Caocci, Giovanni, Molica, Stefano, Griskevicius, Laimonas, Xochelli, Aliki, Kieffer, Jacobien m., Agelink van rentergem, Joost a., Alrjoub, Waleed, Mueller, Anja, Gomes da silva, Maria, Alves da costa, Filipa, Malak, Sandra, Cocks, Kim, and Van de Poll‐Franse, L.V.

Abstract

Background Health-related quality of life (HRQOL) is a critical aspect to consider when making treatment decisions for patients with non-Hodgkin-lymphoma (NHL). This international study by the European Organisation for Research and Treatment of Cancer (EORTC) tested the psychometric properties of two newly developed measures for patients with high-grade (HG)- and low-grade (LG)-NHL: the EORTC QLQ-NHL-HG29 and the EORTC QLQ-NHL-LG20 to supplement the core questionnaire (EORTC QLQ-C30). Methods Overall, 768 patients with HG-NHL (N = 423) and LG-NHL (N = 345) from 12 countries completed the QLQ-C30, QLQ-NHL-HG29/QLQ-NHL-LG20 and a debriefing questionnaire at baseline, and a subset at follow-up for either retest (N = 125/124) or responsiveness to change (RCA; N = 98/49). Results Confirmatory factor analysis showed an acceptable to good fit of the 29 items of the QLQ-NHL-HG29 on its five scales (symptom burden [SB], neuropathy, physical condition/fatigue [PF], emotional impact [EI], and worries about health/functioning [WH]), and of the 20 items of the QLQ-NHL-LG20 on its four scales (SB, PF, EI, and WH). Completion took on average 10 minutes. Test-retest reliability, convergent validity, known-group comparisons, and RCA find satisfactory results of both measures. A total of 31%-78% of patients with HG-NHL and 22%-73% of patients with LG-NHL reported symptoms and/or worries (e.g., tingling in hands/feet, lack of energy, and worries about recurrence). Patients reporting symptoms/worries had substantially lower HRQOL compared to those without. Discussion The use of the EORTC QLQ-NHL-HG29 and QLQ-NHL-LG20 questionnaires in clinical research and practice will provide clinically relevant data to better inform treatment decision-making. Plain language summary The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group developed two questionnaires. These questionnaires measure health-related quality

Published
2023

70. QPOLE:A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction

Author

Van den Heerik, Anne Sophie V.M., Ter Haar, Natalja T., Vermij, Lisa, Jobsen, Jan J., Brinkhuis, Mariel, Roothaan, Suzan M., Leon-Castillo, Alicia, Ortoft, Gitte, Hogdall, Estrid, Hogdall, Claus, Van Wezel, Tom, Lutgens, Ludy C.H.W., Haverkort, Marie A.D., Khattra, Jas, McAlpine, Jessica N., Creutzberg, Carien L., Smit, Vincent T.H.B.M., Gilks, C. Blake, Horeweg, Nanda, Bosse, Tjalling, Van den Heerik, Anne Sophie V.M., Ter Haar, Natalja T., Vermij, Lisa, Jobsen, Jan J., Brinkhuis, Mariel, Roothaan, Suzan M., Leon-Castillo, Alicia, Ortoft, Gitte, Hogdall, Estrid, Hogdall, Claus, Van Wezel, Tom, Lutgens, Ludy C.H.W., Haverkort, Marie A.D., Khattra, Jas, McAlpine, Jessica N., Creutzberg, Carien L., Smit, Vincent T.H.B.M., Gilks, C. Blake, Horeweg, Nanda, and Bosse, Tjalling

Abstract

PURPOSE: Detection of 11 pathogenic variants in the POLE gene in endometrial cancer (EC) is critically important to identify women with a good prognosis and reduce overtreatment. Currently, POLE status is determined by DNA sequencing, which can be expensive, relatively time-consuming, and unavailable in hospitals without specialized equipment and personnel. This may hamper the implementation of POLE-testing in clinical practice. To overcome this, we developed and validated a rapid, low-cost POLE hotspot test by a quantitative polymerase chain reaction (qPCR) assay, QPOLE. MATERIALS AND METHODS: Primer and fluorescence-labeled 5'-nuclease probe sequences of the 11 established pathogenic POLE mutations were designed. Three assays, QPOLE-frequent for the most common mutations and QPOLE-rare-1 and QPOLE-rare-2 for the rare variants, were developed and optimized using DNA extracted from formalin-fixed paraffin-embedded tumor tissues. The simplicity of the design enables POLE status assessment within 4-6 hours after DNA isolation. An interlaboratory external validation study was performed to determine the practical feasibility of this assay. RESULTS: Cutoffs for POLE wild-type, POLE-mutant, equivocal, and failed results were predefined on the basis of a subset of POLE mutants and POLE wild-types for the internal and external validation. For equivocal cases, additional DNA sequencing is recommended. Performance in 282 EC cases, of which 99 were POLE-mutated, demonstrated an overall accuracy of 98.6% (95% CI, 97.2 to 99.9), a sensitivity of 95.2% (95% CI, 90.7 to 99.8), and a specificity of 100%. After DNA sequencing of 8.8% equivocal cases, the final sensitivity and specificity were 96.0% (95% CI, 92.1 to 99.8) and 100%. External validation confirmed feasibility and accuracy. CONCLUSION: QPOLE is a qPCR assay that is a quick, simple, and reliable alternative for DNA sequencing. QPOLE detects all pathogenic variants in the exonuclease domain of the POLE gene. QPOLE will

Published
2023

71. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas

Author

Jamieson, Amy, Vermij, Lisa, Kramer, Claire J.H., Jobsen, Jan J., Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A.D., Slot, Annerie, Nout, Remi A., Oosting, Jan, Carlson, Joseph, Howitt, Brooke E., Ip, Philip P.C., Lax, Sigurd F., McCluggage, W. Glenn, Singh, Naveena, McAlpine, Jessica N., Creutzberg, Carien L., Horeweg, Nanda, Gilks, C. Blake, Bosse, Tjalling, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J.H., Jobsen, Jan J., Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A.D., Slot, Annerie, Nout, Remi A., Oosting, Jan, Carlson, Joseph, Howitt, Brooke E., Ip, Philip P.C., Lax, Sigurd F., McCluggage, W. Glenn, Singh, Naveena, McAlpine, Jessica N., Creutzberg, Carien L., Horeweg, Nanda, Gilks, C. Blake, and Bosse, Tjalling

Abstract

PURPOSE: The clinical significance of the p53-abnormal (p53abn) molecular subtype in stage I low-grade endometrioid endometrial carcinoma (EEC) is debated. We aimed to review pathologic and molecular characteristics, and outcomes of stage I low-grade p53abn EEC in a large international cohort. EXPERIMENTAL DESIGN: Previously diagnosed stage I p53abn EC (POLE-wild-type, mismatch repair-proficient) low-grade EEC from Canadian retrospective cohorts and PORTEC-1&2 trials were included. Pathology review was performed by six expert gynecologic pathologists blinded to p53 status. IHC profiling, next-generation sequencing, and shallow whole-genome sequencing was performed. Kaplan-Meier method was used for survival analysis. RESULTS: We identified 55 stage I p53abn low-grade EEC among 3,387 cases (2.5%). On pathology review, 17 cases (31%) were not diagnosed as low-grade EEC by any pathologists, whereas 26 cases (47%) were diagnosed as low-grade EEC by at least three pathologists. The IHC and molecular profile of the latter cases were consistent with low-grade EEC morphology (ER/PR positivity, patchy p16 expression, PIK3CA and PTEN mutations) but they also showed features of p53abn EC (TP53 mutations, many copy-number alterations). These cases had a clinically relevant risk of disease recurrence (5-year recurrence-free survival 77%), with pelvic and/or distant recurrences observed in 12% of the patients. CONCLUSIONS:A subset of p53abn EC is morphologically low-grade EEC and exhibit genomic instability. Even for stage I disease, p53abn low-grade EEC are at substantial risk of disease recurrence. These findings highlight the clinical relevance of universal p53-testing, even in low-grade EEC, to identify women at increased risk of recurrence.

Published
2023

72. Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period

Author

Tong, Thaïs M.L., Bastiaannet, Esther, Speetjens, Frank M., Blank, Christian U., Luyten, Gregorius P.M., Jager, Martine J., Marinkovic, Marina, Vu, T. H.Khanh, Rasch, Coen R.N., Creutzberg, Carien L., Beenakker, Jan Willem M., Hartgrink, Henk H., Bosch, Jacobus J.J., Kiliç, Emine, Naus, Nicole C., Yavuzyigitoglu, Serdar, van Rij, Caroline M., Burgmans, Mark C., Kapiteijn, Ellen H.W., Tong, Thaïs M.L., Bastiaannet, Esther, Speetjens, Frank M., Blank, Christian U., Luyten, Gregorius P.M., Jager, Martine J., Marinkovic, Marina, Vu, T. H.Khanh, Rasch, Coen R.N., Creutzberg, Carien L., Beenakker, Jan Willem M., Hartgrink, Henk H., Bosch, Jacobus J.J., Kiliç, Emine, Naus, Nicole C., Yavuzyigitoglu, Serdar, van Rij, Caroline M., Burgmans, Mark C., and Kapiteijn, Ellen H.W.

Abstract

Background: Uveal melanoma (UM) is a rare intraocular tumor with a dismal prognosis once metastasized. This study provides a nationwide overview and time trends of patients diagnosed with primary UM in the Netherlands between 1989 and 2019. Methods: A retrospective population-based cohort study based on patients with primary UM from the database of the Netherlands Cancer Registry (NCR), linked with the national population registry Statistics Netherlands on inhabitants’ cause of death. Two time periods (1989–2004, 2005–2019) were compared with descriptive statistics. Kaplan–Meier and (multivariate) Cox proportional hazard models were used to assess changes over time for overall survival (OS) and cancer-specific survival (CSS). Results: In total, 5036 patients were analyzed with a median age of 64.0 years at the time of diagnosis. The number of patients increased over time. In the first (1989–2004) and second (2005–2019) period, 32% versus 54% of the patients received radiotherapy (p < 0.001). The median FU time was 13.4 years. The median OS of the first and second periods was 9.5 (95% CI 8.7–10.3) versus 11.3 years (95% CI 10.3–12.3; p < 0.001). The median CSS was 30.0 years (95% CI NA) in the first period and not reached in the second period (p = 0.008). In multivariate analysis (MVA), female gender (HR 0.85; 95% CI 0.79–0.92, p < 0.001) and radiotherapy treatment (HR 0.73; 95% CI 0.64–0.83, p < 0.001) were associated with better OS. Radiotherapy treatment (HR 0.74; 95% CI 0.61–0.90, p = 0.002) was also associated with better CSS. The period of diagnosis was not associated with OS or CSS. Conclusions: In this study of patients with primary UM, there was a shift to the diagnosis of smaller tumors, possibly due to stage migration. There was also an increase in eye-preserving treatments over time. OS and CSS were modestly improved in the second time period; however, the time per

Published
2023

73. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas

Author

MS Radiotherapie, Cancer, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J H, Jobsen, Jan J, Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A D, Slot, Annerie, Nout, Remi A, Oosting, Jan, Carlson, Joseph, Howitt, Brooke E, Ip, Philip P C, Lax, Sigurd F, McCluggage, W Glenn, Singh, Naveena, McAlpine, Jessica N, Creutzberg, Carien L, Horeweg, Nanda, Gilks, C Blake, Bosse, Tjalling, MS Radiotherapie, Cancer, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J H, Jobsen, Jan J, Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A D, Slot, Annerie, Nout, Remi A, Oosting, Jan, Carlson, Joseph, Howitt, Brooke E, Ip, Philip P C, Lax, Sigurd F, McCluggage, W Glenn, Singh, Naveena, McAlpine, Jessica N, Creutzberg, Carien L, Horeweg, Nanda, Gilks, C Blake, and Bosse, Tjalling

Published
2023

74. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts

Author

MS Radiotherapie, Cancer, Fremond, Sarah, Andani, Sonali, Barkey Wolf, Jurriaan, Dijkstra, Jouke, Melsbach, Sinéad, Jobsen, Jan J., Brinkhuis, Mariel, Roothaan, Suzan, Jurgenliemk-Schulz, Ina, Lutgens, Ludy C.H.W., Nout, Remi A., van der Steen-Banasik, Elzbieta M., de Boer, Stephanie M., Powell, Melanie E., Singh, Naveena, Mileshkin, Linda R., Mackay, Helen J., Leary, Alexandra, Nijman, Hans W., Smit, Vincent T.H.B.M., Creutzberg, Carien L., Horeweg, Nanda, Koelzer, Viktor H., Bosse, Tjalling, MS Radiotherapie, Cancer, Fremond, Sarah, Andani, Sonali, Barkey Wolf, Jurriaan, Dijkstra, Jouke, Melsbach, Sinéad, Jobsen, Jan J., Brinkhuis, Mariel, Roothaan, Suzan, Jurgenliemk-Schulz, Ina, Lutgens, Ludy C.H.W., Nout, Remi A., van der Steen-Banasik, Elzbieta M., de Boer, Stephanie M., Powell, Melanie E., Singh, Naveena, Mileshkin, Linda R., Mackay, Helen J., Leary, Alexandra, Nijman, Hans W., Smit, Vincent T.H.B.M., Creutzberg, Carien L., Horeweg, Nanda, Koelzer, Viktor H., and Bosse, Tjalling

Published
2023

76. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Author

de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B, Ledermann, Jonathan A, Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie-Helene, Kitchener, Henry C, Nijman, Hans W, Kruitwagen, Roy F, Nout, Remi A, Verhoeven-Adema, Karen W, Smit, Vincent T, Putter, Hein, and Creutzberg, Carien L

Published
2016
Full Text
View/download PDF

79. Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial

Author

de Boer, Stephanie M., Nout, Remi A., Jürgenliemk-Schulz, Ina M., Jobsen, Jan J., Lutgens, Ludy C.H.W., van der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Oerlemans, Simone, Putter, Hein, Verhoeven-Adema, Karen W., Nijman, Hans W., and Creutzberg, Carien L.

Published
2015
Full Text
View/download PDF

82. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.

Author

Horeweg, Nanda, Nout, Remi A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., Haverkort, Marie A.D., Mens, Jan Willem M., Slot, Annerie, Wortman, Bastiaan G., de Boer, Stephanie M., Stelloo, Ellen, Verhoeven-Adema, Karen W., Putter, Hein, Smit, Vincent T.H.B.M., Bosse, Tjalling, Creutzberg, Carien L., Creutzberg, C.L., Koper, P.C.M., van Putten, W.L.J., and Dercksen, R.

Published
2023
Full Text
View/download PDF

83. International validation of two EORTC questionnaires for assessment of health‐related quality of life for patients with high‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐HG29) and low‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐LG20)

Author

Oerlemans, Simone, Efficace, Fabio, Kyriakou, Charalampia, Freitas, Ana Carolina, Shamieh, Omar, Creutzberg, Carien L., Lehmann, Jens, Petranovic, Duska, Nagele, Eva, Bredart, Anne, Dong, Dong, Scholz, Christian W., Caocci, Giovanni, Molica, Stefano, Griskevicius, Laimonas, Xochelli, Aliki, Kieffer, Jacobien M., Agelink van Rentergem, Joost A., Alrjoub, Waleed, and Mueller, Anja

Subjects
NON-Hodgkin's lymphoma, QUALITY of life, CONFIRMATORY factor analysis, TEST validity, PSYCHOMETRICS
Abstract

Background: Health‐related quality of life (HRQOL) is a critical aspect to consider when making treatment decisions for patients with non‐Hodgkin‐lymphoma (NHL). This international study by the European Organisation for Research and Treatment of Cancer (EORTC) tested the psychometric properties of two newly developed measures for patients with high‐grade (HG)‐ and low‐grade (LG)‐NHL: the EORTC QLQ‐NHL‐HG29 and the EORTC QLQ‐NHL‐LG20 to supplement the core questionnaire (EORTC QLQ‐C30). Methods: Overall, 768 patients with HG‐NHL (N = 423) and LG‐NHL (N = 345) from 12 countries completed the QLQ‐C30, QLQ‐NHL‐HG29/QLQ‐NHL‐LG20 and a debriefing questionnaire at baseline, and a subset at follow‐up for either retest (N = 125/124) or responsiveness to change (RCA; N = 98/49). Results: Confirmatory factor analysis showed an acceptable to good fit of the 29 items of the QLQ‐NHL‐HG29 on its five scales (symptom burden [SB], neuropathy, physical condition/fatigue [PF], emotional impact [EI], and worries about health/functioning [WH]), and of the 20 items of the QLQ‐NHL‐LG20 on its four scales (SB, PF, EI, and WH). Completion took on average 10 minutes. Test–retest reliability, convergent validity, known‐group comparisons, and RCA find satisfactory results of both measures. A total of 31%–78% of patients with HG‐NHL and 22%–73% of patients with LG‐NHL reported symptoms and/or worries (e.g., tingling in hands/feet, lack of energy, and worries about recurrence). Patients reporting symptoms/worries had substantially lower HRQOL compared to those without. Discussion: The use of the EORTC QLQ‐NHL‐HG29 and QLQ‐NHL‐LG20 questionnaires in clinical research and practice will provide clinically relevant data to better inform treatment decision‐making. Plain language summary: The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group developed two questionnaires.These questionnaires measure health‐related quality of life.The questionnaires are for patients with high‐grade or low‐grade non‐Hodgkin lymphoma.They are called the EORTC QLQ‐NHL‐HG29 and QLQ‐NHL‐LG20.The questionnaires are now internationally validated.This study demonstrates that the questionnaires are reliably and valid, which are important aspects of a questionnaire.The questionnaires can now be used in clinical trials and practice.With the information gathered from the questionnaires, patients and clinicians can better evaluate treatments and discuss the best choice for a patient. This study provides two internationally validated questionnaires for health‐related quality of life assessment in non‐Hodgkin lymphoma: the European Organisation for Research and Treatment of Cancer (EORTC) QLQ‐NHL‐HG29 and EORTC QLQ‐NHL‐LG20. The use of these EORTC questionnaires in research and practice will provide clinically relevant data to better inform treatment decision‐making. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

89. 2022-RA-825-ESGO The impact of age on prognosis in women with endometrial cancer: a pooled analysis of the PORTEC-1, -2 and -3 randomised trials

Author

Wakkerman, Famke Charlotte, primary, De Boer, Stephanie M, additional, Powell, Melanie E, additional, Leary, Alexandra, additional, Fyles, Anthony, additional, Mileshkin, Linda R, additional, Singh, Naveena, additional, Nout, Remi A, additional, Jürgenliemk-Schulz, Ina M, additional, Jobsen, Jan J, additional, Lutgens, Ludy CHW, additional, van der Steen-Banasik, Elsbieta M, additional, Mens, Jan-Willem M, additional, Slot, Annerie, additional, Nijman, Hans W, additional, Smit, Vincent THBM, additional, Bosse, Tjalling, additional, Creutzberg, Carien L, additional, and Horeweg, Nanda, additional

Published
2022
Full Text
View/download PDF

90. 2022-RA-450-ESGO Benefit of adjuvant radiotherapy depends on molecular class of early-stage endometrial cancer

Author

Horeweg, Nanda, primary, Nout, Remi A, additional, Stelloo, Ellen, additional, Lutgens, Ludy CHW, additional, Jobsen, Jan J, additional, Jürgenliemk-Schulz, Ina M, additional, van der Steen-Banasik, Elsbieta M, additional, Mens, Jan-Willem M, additional, Slot, Annerie, additional, Smit, Vincent THBM, additional, Bosse, Tjalling, additional, and Creutzberg, Carien L, additional

Published
2022
Full Text
View/download PDF

91. 2022-RA-683-ESGO The ENSURE trial for women with early-stage endometrial cancer: A randomized controlled trial comparing the effect of a reduced versus usual follow-up schedule on patient satisfaction, health care use, and disease perceptions

Author

Ezendam, Nicole PM, primary, de Rooij, Belle H, additional, Creutzberg, Carien L, additional, Kruitwagen, Roy F, additional, van Lonkhuijzen, Luc RCW, additional, Apperloo, Mirjam JA, additional, Gerestein, Kees, additional, Baalbergen, Astrid, additional, Boll, Dorry, additional, Caroline Vos, M, additional, and van de Poll-Franse, Lonneke V, additional

Published
2022
Full Text
View/download PDF

92. 2022-RA-809-ESGO Underlying causes and prognosis of mismatch repair deficiency in endometrial cancer other thanMLH1promoter hypermethylation

Author

Kaya, Merve, primary, Post, Cathalijne, additional, Tops, Carli M, additional, Stelloo, Ellen, additional, Nielsen, Maartje, additional, Powell, Melanie E, additional, Leary, Alexandra, additional, Mileshkin, Linda R, additional, Bessette, Paul, additional, de Boer, Stephanie M, additional, Jürgenliemk-Schulz, Ina M, additional, Lutgens, Ludy, additional, Jobsen, Jan J, additional, van der Steen-Banasik, Elzbieta M, additional, Nout, Remi A, additional, Horeweg, Nanda, additional, van Wezel, Tom, additional, Smit, Vincent, additional, Creutzberg, Carien L, additional, and Bosse, Tjalling, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results